GlassScriptPhysician profile
Roderick S Kim
NPI 1922066984
$1,984.84
in general payments reported to CMS, 2019-2025
32 companies · $182 in 2025
The $182 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $42.52 · 2021: $231 · 2022: $483 · 2023: $442 · 2024: $459 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,083.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $246.30 | 2019-2024 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.57 | 2022-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $145.20 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $141.91 | 2021-2024 | Gardasil 9, Capvaxive, Gardasil |
| Daiichi Sankyo INC. | $136.57 | 2021-2025 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $114.74 | 2022-2024 | Eliquis |
| Lilly USA, LLC | $110.06 | 2019-2025 | Jardiance, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $82.89 | 2022-2024 | |
| Glaxosmithkline, LLC. | $75.35 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Abbvie INC. | $71.76 | 2021-2023 | |
| Amgen INC. | $58.31 | 2021-2025 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $55.31 | 2020-2021 | |
| Astellas Pharma US INC | $53.29 | 2022-2023 | Veozah |
| Sanofi Pasteur INC. | $52.51 | 2019-2023 | |
| Pfizer INC. | $51.74 | 2019-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $39.24 | 2023-2024 | Cologuard Collection Kit |
| Dexcom, INC. | $32.27 | 2023 | Dexcom G6 Transmitter |
| Abbott Laboratories | $31.60 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $30.67 | 2021-2024 | Airsupra |
| Inspire Medical Systems, INC. | $29.00 | 2024 | Inspire |
| Alexion Pharmaceuticals, INC. | $24.27 | 2022 | |
| Xeris Pharmaceuticals, INC. | $23.84 | 2024 | Gvoke Hypopen |
| Sumitomo Pharma America, INC. | $23.55 | 2025 | Gemtesa |
| Philips North America LLC | $22.75 | 2021 | |
| Grt US Holding, INC. | $21.78 | 2022 | |
| Antares Pharma, INC. | $19.95 | 2024 | Xyosted |
| Takeda Pharmaceuticals U.S.A., INC. | $19.53 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.42 | 2023 | Xifaxan |
| Radius Health, INC. | $17.79 | 2023 | Tymlos |
| Actelion Pharmaceuticals US, INC. | $17.32 | 2022 | |
| Baxter Healthcare | $14.32 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Gilead Sciences, INC. | $14.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roderick Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.